Oct 28, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Oct 25, 2019 - During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
Oct 25, 2019 - During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
Oct 24, 2019 - Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven third-quarter sales. However, genericization of key drugs and increased competition are concerns.
Oct 24, 2019 - During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Oct 23, 2019 - Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
Oct 23, 2019 - Despite almost day-to-day market fluctuations, a few corporate behemoths surged in Wall Street. Some of these are set to beat earnings estimate in the ongoing reporting cycle.
Oct 21, 2019 - During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
Oct 21, 2019 - With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Oct 21, 2019 - Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.